DALLAS, TX -- May 15th, 2026 -- StimCell Energetics Inc. (STME): Stonegate Initiates Coverage on StimCell Energetics Inc. (STME). StimCell is a single-product company focused on eBalance®. Rather than managing a broad portfolio, the Company is centered on advancing one core platform. The current emphasis appears to be on redesigning eBalance into a compact consumer unit optimized for home use, and the Company’s SEC filings state that StimCell is focused on the discovery, development, and commercialization of both therapeutic and non-therapeutic products that promote general wellness
How the Device Works: StimCell describes eBalance as a non-invasive microcurrent system that delivers pre-programmed electrical stimulation through the body using hand bars and footplates in a closed-loop circuit. The Company states that the device measures the electrical current returning from the body and interprets that return signal as an indicator of the user’s energetic state. We view this biofeedback capability as a notable part of the product story because it suggests eBalance is being positioned as a system that both delivers current and monitors the body’s response. It is believed that this current indicates metabolic health, leading to the potential for significant value derived from being able to easily monitor these levels.
Company-Reported Trial Results: One of the more important pieces of public support for the story is the company’s trial-results page, which describes a 12- week observational clinical trial approved by Health Canada involving 30 diabetic participants treated twice weekly for 15 minutes. According to the Company, mean blood pressure declined and plasma insulin levels in a 22-patient subset also fell. The Company presents these findings as evidence of promising trends in blood pressure, fasting blood sugar, and plasma insulin, and states that no significant adverse events were reported. In our view, these results provide early human outcome data around the device; however, it is important to note that this is company-reported pilot-style evidence rather than a registration-style clinical trial.
Science and Validation: Beyond the company-reported human observational data, StimCell has also taken steps to build a more formal scientific narrative around the device’s mechanism of action. In December 2025, the company announced a study with the St. Boniface Hospital Albrechtsen Research Centre and a University of Manitoba-affiliated investigator to evaluate eBalance’s impact on mitochondrial function in cultured sensory neurons. The announced work includes measurements such as oxygen consumption rates, ATP production, basal and maximal respiration, spare respiratory capacity, coupling efficiency, proton leak, AMPK activity, and respiratory proteins. We are encouraged by the Company seeking mechanistic support around cellular energy production and mitochondrial function.
Execution and Capital Needs: The Company remains early in commercialization, and, in our view, execution is still the key issue. STME is continuing work to redesign the device for home use under its ADM Tronics partnership. This redesign has the goal of transforming eBalance into a compact, affordable consumer unit optimized for home use, and that research and development spending increased meaningfully as a result. We believe this makes the near-term story less about broad financial performance and more about successfully finishing the product redesign.
Valuation: We rely on a DCF framework to guide our valuation. Using a 20% discount rate and a shares outstanding CAGR range of 1.25% to 3.75%, our DCF implies a valuation range of $0.29 to $0.66 per share, with a midpoint of $0.44. Please see the valuation page for further details.
